Form 4: Omnicell Executive Reports Stock Transactions

Omnicell's EVP & Chief Legal/Admin Officer, Corey J. Manley, reported the vesting of performance-based restricted stock units and subsequent sales under a Rule 10b5-1 plan.

Summary

• Corey J. Manley, EVP & Chief Legal/Admin Officer of Omnicell, Inc. (OMCL), reported transactions involving the company's common stock.
• On March 15, 2026, 22,445 performance-based restricted stock units (RSUs) vested, reflecting 100% of the target amount after the Compensation Committee determined performance criteria were met on March 5, 2026.
• These RSUs were originally granted on March 15, 2025, subject to Omnicell meeting certain stock performance objectives compared to the S&P 1000 Healthcare Index.
• Following the vesting, 3,819 shares were withheld on March 15, 2026, at a price of $34.4 per share to cover tax obligations.
• An additional 7,405 shares were sold on March 16, 2026, at an exact price of $34.69 per share, pursuant to a Rule 10b5-1 trading plan adopted on June 13, 2025.
• After these transactions, Corey J. Manley beneficially owns 96,717.3392 shares of Omnicell Common Stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive. The vesting of performance-based RSUs indicates the company met its performance targets, which is positive, but the executive's sale of shares, even if planned, slightly offsets this.

Positives

• The vesting of 22,445 performance-based restricted stock units indicates that Omnicell met its stock performance objectives relative to the S&P 1000 Healthcare Index, suggesting positive company performance during the measurement period.

Negatives

• The sale of 7,405 shares by a key executive, even if pre-planned, could be perceived by some investors as a lack of confidence, although it is a routine part of executive compensation and liquidity management.

Future Outlook

The remaining performance-based restricted stock units will vest in equal quarterly increments once every three months over a three-year period, specifically on each May 15, August 15, November 15, and February 15.

Industry Context

StockSavvy.ai notes that the use of performance-based restricted stock units tied to an industry index like the S&P 1000 Healthcare Index is a common and effective executive compensation strategy, aligning management incentives with shareholder value and sector-specific performance. The subsequent sale under a Rule 10b5-1 plan is also a standard practice for executives to manage personal finances while avoiding accusations of insider trading.

Comparison to Industry Standards

• The structure of performance-based restricted stock units, where vesting is contingent on meeting specific performance objectives relative to an industry index (S&P 1000 Healthcare Index), is a widely adopted practice in executive compensation across various industries, including healthcare technology.
• The adoption of a Rule 10b5-1 trading plan for stock sales is a standard compliance measure for executives, comparable to practices at peer companies like Cerner (now Oracle Health) or Epic Systems, ensuring pre-scheduled transactions and mitigating insider trading concerns.

Stakeholder Impact

• Shareholders are informed of executive compensation realization and planned stock sales, providing transparency into management's equity holdings and trading activities.

Next Steps

• The remaining performance-based restricted stock units will continue to vest in equal quarterly increments over the next three years on May 15, August 15, November 15, and February 15.

Key Dates

Recommendation

This Form 4 details routine executive compensation vesting and pre-planned stock sales, which are common occurrences and typically do not provide a strong signal for a 'buy' or 'sell' recommendation. The transactions reflect standard executive liquidity management and the fulfillment of compensation agreements rather than a change in the company's fundamental outlook.

Keywords

OMNICELL, OMCL, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, 10b5-1 Plan, Executive Compensation, Stock Sale